You are here:
sapropterin (Kuvan)
Advice
In the absence of a submission from the holder of the marketing authorisation.
sapropterin (Kuvan) is not recommended for use within NHSScotland for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with phenylketonuria (PKU) and for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with tetrahydrobiopterin (BH4) deficiency.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Drug Details
| Drug Name: | sapropterin (Kuvan) |
|---|---|
| SMC Drug ID: | 558/09 |
| Manufacturer: | Merck Serono Ltd |
| Indication: | For the treatment of hyperphenylalaninaemia (HPA) |
| BNF Category: | |
| Sub Category: | 9.4 Oral nutrition |
| Submission Type: | Non submission |
| Status: | Not Recommended |
| Date Advice Published: | 8 June 2009 |